From Clinical Clearance to Commercial Traction: The AI Gap MedTech Can No Longer Afford to Ignore

Co-authored by Linda Bernier, SmartTRAK | Denise Steinbring, Chief Outsiders

MedTech has a brilliant innovation problem: not because the science is weak, but because extraordinary technology keeps failing commercially, not clinically.

The numbers are hard to ignore: 74% of U.S.-based medical device startups fail to return capital to investors regardless of clinical merit or regulatory clearance. The #1 cause of startup failure, across every post-mortem study, isn't scientific or regulatory. It's no market demand.

We see this in the data constantly. Technologies representing genuine clinical advances never reach scale, not because they lacked efficacy, but because the commercial infrastructure to support them was never built.

The Commercial Gap and the AI Blind Spot Inside It

The MedTech industry has embraced AI impressively in product development, surgical robotics, and diagnostics. What remains largely absent is AI as a commercial accelerator. Ask early-stage founders about their demand generation strategy or how they plan to build commercial traction with a lean team, and the answers are frequently vague, underdeveloped, or absent entirely.

This gap is widening, and it's expensive. Research shows only 19% of healthcare SMBs have reached full AI adoption, one of the lowest rates across all industries. Meanwhile, companies that do integrate AI into commercial workflows are 3.7× more likely to meet sales quota. The first-mover window is still open. It won't stay that way.

Where Intelligence Becomes the Differentiator

From SmartTRAK's vantage point serving marketing, product and business development teams across orthopedics, wound care, regenerative medicine, and neuro therapy, the pattern is consistent: the companies struggling most aren't those without good products. They're the ones making go-to-market decisions without adequate market intelligence.

Which physician segments are performing the procedures your device targets — at volume? Which health systems are early adopters versus entrenched incumbents? Where are competitors gaining ground, and where are their clinical claims weakest? Which payer policies are shifting in ways that open or close reimbursement windows?

These aren't research questions. They're commercial operations questions and they require current, curated, MedTech-specific intelligence to answer with confidence. The most dangerous moment in a MedTech launch is when a commercial team operates on assumption rather than insight.

What a Real AI Commercial OS Actually Does

The answer isn't more tools. It's an integrated architecture. A genuine AI Commercial Operating System has four capabilities working in sequence:

• AI-driven demand generation — Machine learning scores and prioritizes accounts using procedure volume, claims data, and clinical profile matching. Automated outreach sequences calibrated to specialty, role, and buying stage. A two-person team executing at the velocity of ten.
• Commercial intelligence — Real-time monitoring of competitive activity, payer policy shifts, and health system purchasing signals. This is where platforms like SmartTRAK move from research subscription to operational infrastructure, putting curated MedTech intelligence directly into the commercial workflow.
• Workflow automation — Automated follow-up sequencing, meeting preparation, post-call documentation, and VAC package generation that reclaims actual selling time.
• Measurement architecture — Tracking leading indicators (account penetration, outreach response rates, pipeline velocity) rather than waiting on lagging revenue signals. This is what separates teams generating 2–3× ROI from those who can't demonstrate any return at all.

The Five Elements Most Chronically Skipped

Chief Outsiders' Growth Gears® framework for MedTech commercialization identifies 18 planning elements across Insight, Strategy, and Execution. Five are most chronically underfunded — and all five require intelligence to execute:

• Customer & Stakeholder Insight — Most companies map the clinician but fail to model the IDN administrator, procurement committee, and payer — the stakeholders who control the actual purchase decision.
• KOL & Advisory Board Strategy — This requires 18–24 months of cultivation. It cannot begin at launch.
• Pricing, Reimbursement & Packaging — Price must be defensible to Value Analysis Committees, not just clinically compelling.
• Value Analysis Committee Tools — Economic calculators and evidence dossiers are commercial infrastructure, not afterthought sales support.
• Budget Allocation & Commercial P&L — Model the full cost of commercial execution — headcount, programs, tools, KOL activation — before you raise.

Join the Conversation at In2Data

If this challenge resonates — turning market intelligence into commercial traction — SmartTRAK's In2Data conference on November 4th at The Gaylord Hotel in Dallas is built for exactly this conversation. Our Insights to Revenue panel will bring together MedTech commercial leaders to explore how organizations operationalize intelligence to drive pipeline acceleration and faster time-to-revenue. Denise Steinbring will be among the esteemed panelists.

Learn more and register at SmartTRAK.com/in2data →

The Imperative

The companies that define the next decade of MedTech won't be those with the best devices alone. They'll be those that treat commercial capability as a core competency from Day One, raising capital that explicitly funds commercial execution, deploying AI as a commercial multiplier, and using intelligence to ensure every go-to-market decision is grounded in current market reality.

The technology is ready. The intelligence exists. The frameworks are proven. Now build the commercial architecture to match the quality of your innovation.

Linda Bernier is COO at SmartTRAK, the leading MedTech market intelligence platform for Orthopedics, Wound Care, Regenerative Medicine, and Neuro Therapy. Learn more at SmartTRAK.com.

Denise Steinbring is an Area Managing Partner with Chief Outsiders specializing in MedTech commercial strategy. Learn more at chiefoutsiders.com.

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.